ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

NNC0581-0001

A development code.

Its studies are mostly in Fatty Liver, led by Novo Nordisk.

Furthest: phase 1, since Oct 26, 20222 company-led studies, 1 open or runningNext primary completion: Oct 11, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk21 open or runningphase 1since Oct 26, 2022Oct 26, 2022Oct 11, 2027phase 1 · NCT06891365

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 26, 2022First study: phase 1 study in Fatty LiverFirst studyNCT05599945 · 48 enrolled · United Kingdom
  2. Mar 17, 2025Phase 1 study in Fatty LiverNCT06891365 · 48 planned · United Kingdom

Ahead

  1. Oct 11, 2027Primary completion: phase 1 study in Fatty LiverNCT06891365

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06891365Fatty Liver · United Kingdom1RecruitingOct 11, 202748
NCT05599945Fatty Liver · United Kingdom1CompletedAug 29, 202548

How it is read

Names in the registry

  • “NNC0581-0001”, 2 entries

Codes read as this program: NNC05810001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.